Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese (vol 34, pg 19, 2018)

被引:0
|
作者
Nose, Daisuke [1 ]
Shiga, Yuhei [1 ]
Ueda, Yoko [1 ]
Idemoto, Yoshiaki [1 ]
Tashiro, Kohei [1 ]
Suematsu, Yasusnori [1 ]
Kuwano, Takashi [1 ]
Kitajima, Ken [1 ]
Saku, Keijiro [1 ,2 ]
Miura, Shin-ichiro [1 ,2 ]
机构
[1] Fukuoka Univ, Dept Cardiol, Sch Med, Jonan Ku, 7-45-1 Nanakuma, Fukuoka, Fukuoka 8140180, Japan
[2] Fukuoka Univ, Sch Med, Dept Mol Cardiovasc Therapeut, Fukuoka, Fukuoka, Japan
关键词
Coronary artery disease; Multidetector-row computed tomography; Pro-protein convertase subtilisin/kexin type 9; Statin;
D O I
10.1007/s00380-018-1237-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The ability of pro-protein convertase subtilisin/kexin type 9 (PCSK9) levels to predict the presence or severity of coronary artery disease (CAD) remains controversial. The purpose of this study was to investigate these associations. We enrolled 393 patients who were clinically suspected to have CAD or who had at least one cardiac risk factor and underwent multidetector-row computed tomography coronary angiography. The presence of CAD (≥50% coronary stenosis), the number of significantly stenosed coronary vessels, and plasma levels of PCSK9 by ELISA were analyzed. Plasma PCSK9 levels (log-transformed data) were significantly associated with the presence of CAD. Next, we divided the patients into two groups (non-statin and statin groups) according to statin treatment. PCSK9 levels in the non-statin group were significantly lower than those in the statin group. There were no significant differences in PCSK9 levels between the absence and presence of CAD in the statin group. However, in the non-statin group, PCSK9 levels in patients with CAD were significantly higher than those in patients without CAD. PCSK9 levels, in addition to age, gender, BMI, DM and HDL-C, were independently associated with the presence of CAD by a multivariable analysis. In conclusion, our results demonstrated that plasma PCSK9 levels may be a marker for evaluating the presence of CAD. © 2018, Springer Japan KK, part of Springer Nature.
引用
收藏
页码:29 / 32
页数:4
相关论文
共 50 条
  • [31] Plasma PCSK9 is associated with the severity of coronary artery lesions in patients with acute coronary syndrome
    Cariou, B.
    Guerin, P.
    Pichelin, M.
    Arnaud, L.
    Le May, C.
    Prieur, X.
    Guyomarch, B.
    Probst, V.
    DIABETOLOGIA, 2016, 59 : S530 - S530
  • [32] Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
    Nozue, Tsuyoshi
    Hattori, Hiroaki
    Ogawa, Kazuyuki
    Kujiraoka, Takeshi
    Iwasaki, Tadao
    Hirano, Tsutomu
    Michishita, Ichiro
    LIPIDS IN HEALTH AND DISEASE, 2016, 15 : 1 - 7
  • [33] Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
    Tsuyoshi Nozue
    Hiroaki Hattori
    Kazuyuki Ogawa
    Takeshi Kujiraoka
    Tadao Iwasaki
    Tsutomu Hirano
    Ichiro Michishita
    Lipids in Health and Disease, 15
  • [34] Low PCSK9 plasma level is an independent predictor of coronary atherosclerotic burden in patients with stable coronary artery disease
    Caselli, C.
    Ragusa, R.
    Del Turco, S.
    De Graaf, M.
    Basta, G.
    Scholte, A.
    De Caterina, R.
    Neglia, D.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3780 - 3780
  • [35] Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
    Musunuru, Kiran
    ANNUAL REVIEW OF MEDICINE, VOL 72, 2021, 2021, 72 : 447 - 458
  • [36] ASSOCIATION OF APOLIPOPROTEINS PLASMA LEVELS WITH PCSK9 IN TYPE 2 DIABETES MELLITUS
    Baudin, Bruno
    Nekaies, Ymene
    Baudin, Bruno
    Kelbousi, Sami
    Sakly, Mohsen
    Attia, Nebil
    ATHEROSCLEROSIS, 2017, 263 : E273 - E274
  • [37] PCSK9 GENETIC VARIANTS IN PATIENTS WITH CORONARY ARTERY DISEASE - A PILOT STUDY
    Ashavaid, T. F.
    Bane, A.
    Ponde, C. K.
    Rajani, R. M.
    Pillai, S.
    ATHEROSCLEROSIS, 2018, 275 : E224 - E225
  • [38] Effect of PCSK9 inhibition on platelet reactivity in coronary artery disease patients
    Galli, Lukas
    Ondracek, Anna
    Seidl, Veronika
    Hofbauer, Thomas
    Zedan, Yasmin
    Schrutka, Lore
    Krychtiuk, Konstantin
    Lang, Irene M.
    Speidl, Walter
    Distelmaier, Klaus
    WIENER KLINISCHE WOCHENSCHRIFT, 2019, 131 : 372 - 373
  • [39] Association between Plasma Sestrin2 Levels and the Presence and Severity of Coronary Artery Disease
    Kishimoto, Yoshimi
    Aoyama, Masayuki
    Saita, Emi
    Ikegami, Yukinori
    Ohmori, Reiko
    Kondo, Kazuo
    Momiyama, Yukihiko
    DISEASE MARKERS, 2020, 2020
  • [40] Plasma PCSK9 levels and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography
    Panahi, Y.
    Ghahrodi, M. S.
    Jamshir, M. S.
    Safarpour, M. A.
    Pirro, M.
    Bianconi, V.
    Farahani, M. M.
    Banach, M.
    Sahebkar, A.
    EUROPEAN HEART JOURNAL, 2019, 40 : 472 - 472